New research highlights a significant link between metabolic dysfunction-associated steatotic liver disease (MASLD), formerly ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

Medically reviewed by Robert Burakoff, MD Fatty liver disease is a health condition in which fat builds up in the liver. This ...

Often symptomless, fatty liver disease is becoming a leading cause of liver cancer. Learn the role of daily habits, early ...

New European guidelines redefine Metabolic dysfunction-associated steatotic liver disease (MASLD) care, offering clearer ...

South Korea: A large population-based study from South Korea has revealed a significant association between cholecystectomy ...

A new analysis from the Chile BiLS study evaluated the reliability of ultrasound imaging for diagnosing SLD in a high-risk ...

China: A large-scale U.S. analysis has revealed that people living with both type 2 diabetes (T2DM) and chronic kidney ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), including metabolic dysfunction-associated steatohepatitis (MASH), is the most common aetiology of liver disease worldwide. MASLD is ...

Steatotic liver disease (SLD) was highly prevalent among adults with cardiometabolic risk factors, prolonged alcohol intake, or both combined and affected 70% of participants overall.

Source Reference: Ochoa-Allemant P, et al "Adverse liver outcomes, cardiovascular events, and mortality in steatotic liver disease" JAMA Intern Med 2025; DOI: 10.1001/jamainternmed.2025.1809.

Although Wegovy (semaglutide) is often used as a weight-loss medicine, it is well-known to be protective for the heart. Similarly, telmisartan is in the class of drugs that protect the heart, even in ...